Press Releases Knight Therapeutics Inc. BOERSE MUENCHEN

Equities

04K

CA4990531069

Market Closed - BOERSE MUENCHEN Other stock markets 01:14:26 29/06/2024 am IST			5-day change	1st Jan Change
3.9 ^EUR	+2.09%		+5.98%	+8.94%

09/05	Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1	MT
09/05	Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Knight Therapeutics Reports First Quarter 2024 Results	09/05	GL
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America	09/05	GL
Knight Therapeutics Inc. announces voting results from the Annual General Meeting	09/05	GL
Knight Therapeutics Inc. announces voting results from the Annual General Meeting	09/05	AQ
Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City	07/05	GL
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call	02/05	GL
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04	GL
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity	28/03	GL
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results	21/03	GL
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call	14/03	GL
Knight Therapeutics Announces Launch of Minjuvi® in Brazil	29/02	GL
Knight Therapeutics Announces Launch of Minjuvi® in Brazil	29/02	AQ
Knight Therapeutics Inc. Celebrates its First Decade of Success	28/02	GL
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil	22/02	GL
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil	22/02	AQ
Knight Therapeutics Announces Launch of Bijuva® in Canada	06/02	GL
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203	25/01	GL
Knight Therapeutics Announces Product Launch for IMVEXXY® in Canada	04/01	GL
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada	20/12	AQ
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada	19/12	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Knight Therapeutics Inc. BOERSE MUENCHEN

Equities

04K

CA4990531069

Press Releases

Filters